Ticker brief
ONCY
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
38
authors 14d
10
crowd 14d
+0.0σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-27 · now +0.20 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @JTE_ThetaCo | C | +0.22 | 11 | +0.45 |
| @HunterAllen4 | C | -1.66 | 8 | +0.59 |
| @InvestmentGuru_ | C | +0.12 | 4 | +0.42 |
| @PepInvestStocks | B | -0.34 | 4 | +0.58 |
| @investmattallen | C | -0.47 | 3 | +0.35 |
| @PennyboisTrades | C | +1.11 | 3 | +0.40 |
| @MacroGekko | C | -1.52 | 2 | +0.47 |
| @MrMTrades | C | +1.56 | 1 | +0.50 |
| @BiopharmIQ | B | · | 1 | +0.25 |
| @dmdt14 | C | -1.88 | 1 | +0.20 |
Recent signals30of 38 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-27 | @dmdt14 | +0.20 | Lists ONCY support and two resistance levels with conditional bullishness. | · | tweet ↗ |
| 2026-08-25 | @PennyboisTrades | +0.35 | Oncolytics received written FDA feedback on a potential pivotal expansion and accelerated-approval pathway. | · | tweet ↗ |
| 2026-08-25 | @JTE_ThetaCo | +0.75 | Says ONCY has a huge addressable market to conquer. | · | tweet ↗ |
| 2026-08-25 | @JTE_ThetaCo | +0.65 | Oncolytics announced FDA alignment on a potential registrational and accelerated-approval pathway for pelareorep. | · | tweet ↗ |
| 2026-08-21 | @HunterAllen4 | +0.72 | Presents a paid, risk-qualified bull case for ONCY as a systemic oncolytic-immunotherapy platform. | · | tweet ↗ |
| 2026-08-21 | @HunterAllen4 | +0.55 | Reports written FDA alignment on a potential pivotal ONCY trial expansion and details partner validation. | · | tweet ↗ |
| 2026-08-21 | @HunterAllen4 | +0.65 | Builds a long-horizon ONCY platform thesis from mechanistic, clinical and regulatory evidence. | · | tweet ↗ |
| 2026-08-21 | @HunterAllen4 | +0.50 | Reports FDA feedback aligning ONCY on a potential registrational pathway for pelareorep. | · | tweet ↗ |
| 2026-08-20 | @PennyboisTrades | +0.50 | Presents an ONCY watch setup with support, invalidation, resistance, and an MRNA comparison. | · | tweet ↗ |
| 2026-08-20 | @PepInvestStocks | +0.65 | Argues pelareorep's mechanism makes ONCY a partnership or acquisition candidate. | · | tweet ↗ |
| 2026-08-20 | @PepInvestStocks | +0.60 | Argues data from over 1,300 patients materially lowers ONCY clinical-development risk. | · | tweet ↗ |
| 2026-08-20 | @PepInvestStocks | +0.50 | Company says FDA feedback supports a registrational path and possible accelerated approval. | · | tweet ↗ |
| 2026-08-20 | @PepInvestStocks | +0.55 | Frames pelareorep as a diversified immunotherapy platform with Fast Track status and extensive safety data. | · | tweet ↗ |
| 2026-08-19 | @HunterAllen4 | +0.60 | Paid thesis frames ONCY as a multi-indication GI oncology platform with clinical risks. | · | tweet ↗ |
| 2026-08-19 | @HunterAllen4 | +0.65 | Paid long-form thesis highlights ONCY efficacy, partnerships and asymmetric upside. | · | tweet ↗ |
| 2026-08-19 | @HunterAllen4 | +0.55 | Paid thesis combines FDA alignment, insider buying and short-interest mechanics. | · | tweet ↗ |
| 2026-08-19 | @HunterAllen4 | +0.50 | Reports FDA feedback supporting a potential registrational and accelerated-approval path. | · | tweet ↗ |
| 2026-08-18 | @InvestmentGuru_ | +0.35 | Reports FDA openness to an accelerated-approval pathway if REO 033 data are strong. | · | tweet ↗ |
| 2026-08-18 | @MacroGekko | +0.50 | Reports positive written FDA feedback and a potential registration pathway. | · | tweet ↗ |
| 2026-08-18 | @investmattallen | +0.40 | ONCY collaborations with major pharmaceutical firms broaden testing of pelareorep combinations. | · | tweet ↗ |
| 2026-08-18 | @BiopharmIQ | +0.25 | Biotech news roundup lists trial, regulatory, acquisition and access catalysts with opening moves. | · | tweet ↗ |
| 2026-08-18 | @JTE_ThetaCo | +0.70 | Says ONCY has multiple milestones ahead and is only getting started. | · | tweet ↗ |
| 2026-08-18 | @investmattallen | +0.40 | Management reports FDA feedback that clarifies potential accelerated and full approval endpoints. | · | tweet ↗ |
| 2026-08-18 | @PennyboisTrades | +0.35 | Reports constructive FDA feedback on possible trial expansion and accelerated approval path. | · | tweet ↗ |
| 2026-08-18 | @InvestmentGuru_ | +0.55 | Presents a constructive, catalyst-driven ONCY biotech setup contingent on Part A clinical data. | · | tweet ↗ |
| 2026-08-18 | @InvestmentGuru_ | +0.35 | Reports written FDA feedback supporting a potential pivotal expansion and registrational pathway. | · | tweet ↗ |
| 2026-08-18 | @InvestmentGuru_ | +0.45 | Presents a high-risk ONCY platform thesis with clinical upside, dilution risk and data catalysts. | · | tweet ↗ |
| 2026-08-18 | @JTE_ThetaCo | +0.65 | Calls the development a massive win for ONCY. | · | tweet ↗ |
| 2026-08-18 | @JTE_ThetaCo | +0.50 | Oncolytics aligned with FDA on a potential registrational path for REO 033. | · | tweet ↗ |
| 2026-08-18 | @investmattallen | +0.25 | Describes ONCY's pelareorep program, cancer indications and treatment of over 1,300 patients. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.